Viewing Study NCT07032727


Ignite Creation Date: 2025-12-25 @ 5:08 AM
Ignite Modification Date: 2025-12-26 @ 4:12 AM
Study NCT ID: NCT07032727
Status: RECRUITING
Last Update Posted: 2025-12-15
First Post: 2025-06-16
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Sponsor: M.D. Anderson Cancer Center
Organization:

Organization Data

Organization:
Class: OTHER
Study ID: 2025-0520
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None INDUSTRY View